Objectives of Study:
|
By comparing the treatment group and the control group using ' Xiangzhi medicine line ' and ' sterile rubber drainage strip ' two different drainage methods of related treatment, the size of the tumor between the two groups was observed. Before and after symptom score ( local skin changes, breast pain, laboratory indicators ) ; laboratory indexes ( immunoglobulin IgG, IgM, IgA, complement C3, complement C4, flow cytometry detection of CD3 ( + ), CD3 ( + ) CD4 ( + ), CD3 ( + ) CD8 ( + ), CD4 / CD8, C-reactive protein, and lymphocyte count in T cell subsets ) ; safety indicators ( body temperature, heart rate, respiration, pulse, blood pressure, blood routine + CRP, liver and kidney function, ECG ) ; statistical indicators ( recovery time of unresectable cases, recovery rate of unresectable cases, unresectable rate, one-time suture rate of surgical cases ). To evaluate the efficacy, clinical value and safety of ' Xiangzhi medicated thread ' in the treatment of GLM in abscess stage, so as to seek an ideal treatment for this disease and provide new ideas for clinical treatment.
|
Inclusion criteria
|
( 1 ) The clinical symptoms were inflammation, color ultrasound examination and breast masses were punctured by color ultrasound-guided core biopsy needle, and pathological examination confirmed GLM ;
( 2 ) The clinical symptom stage is abscess stage ;
( 3 ) Breast skin without damage ;
( 4 ) Non-lactation onset, female ;
( 5 ) The affected breast is single pus cavity, or multiple pus cavity with pus cavity number ≤ 2 ;
( 6 ) Mass with obvious fluctuation, without breast incision and drainage before admission ;
( 7 ) The informed consent of the patient and the voluntary signing of the informed agreement by the patient meet the basic requirements of the Ethics Committee.
|
Exclusion criteria:
|
( 1 ) Women in pregnancy or lactation ;
( 2 ) The local skin of the breast becomes thinner, which is estimated by our group of clinicians to be broken within 10 days ;
( 3 ) Patients with previous primary diseases such as heart and lung, liver and kidney, tuberculosis ;
( 4 ) Patients with breast surgery or hormone therapy in recent 3 months ;
( 5 ) Patients with breast cancer ;
( 6 ) Poor compliance or a history of mental illness, unable to cooperate with treatment and follow-up ;
( 7 ) Patients with severe primary diseases such as heart and lung, liver and kidney, tuberculosis ;
( 8 ) Those who received other drugs within 3 months or had evidence of drug abuse or dependence recently.
|